Platelet Rich Plasma Versus Corticosteroids in Hip Osteoarthritis Pain

Last updated: March 11, 2025
Sponsor: LifeBridge Health
Overall Status: Active - Recruiting

Phase

4

Condition

Osteoarthritis

Treatment

Platelet Rich Plasma Joint Injection

Corticosteroid Injection

Clinical Study ID

NCT06793982
2084137
  • Ages 21-80
  • All Genders

Study Summary

Prospective, single-center that may go on to being multicenter, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Provision of signed and dated informed consent form

  • Stated willingness to comply with all study procedures and availability for theduration of the study

  • Male or female, aged 21-80 years

  • Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III Hiposteoarthritis

  • Indicated for a Hip injection to treat Hip OA symptoms

Exclusion

Exclusion Criteria:

  • Any injections into the target Hip within three months

  • Current overlying skin infection

  • Current or previous diagnosis of "chronic pain"

  • Opioid tolerant at time of screening (for a week or longer, at least 60 mg ofmorphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oralhydromorphone daily or an equianalgesic dose of another opioid.)

  • Allergy to any potential ingredients or medications utilized in any of the twogroups

  • Treatment with another investigational drug or other intervention for pain

  • Diagnosis of Diabetes Mellitus

  • If female, pregnant or planning to be pregnant within the following 3 months orstudy duration

  • Any condition(s) or diagnosis, both physical or psychological, or physical examfinding in the opinion of the investigator that would precludes participation

Study Design

Total Participants: 54
Treatment Group(s): 2
Primary Treatment: Platelet Rich Plasma Joint Injection
Phase: 4
Study Start date:
February 21, 2024
Estimated Completion Date:
December 01, 2025

Study Description

Platelet rich plasma has become increasingly utilized as a treatment option for Hip osteoarthritis. Corticosteroids is currently an approved medication to treat the symptoms of the Hip osteoarthritis. There is limited evidence in a prospective randomized manner powered adequately to determine a difference between these treatments for pain associated with Hip osteoarthritis.

Prospective, single center that may go on to be multi-center, single blind (participant), randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of Hip osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.

Connect with a study center

  • Sinai Hospital of Baltimore

    Baltimore, Maryland 21215
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.